New and Emerging Trends in Prostate Cancer
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Genitourinary Oncology".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 173
Special Issue Editors
Interests: stereotactic ablative radiotherapy (SABR); prostate cancer oligometastases and metastases directed therapy (MDT); personalized prostate cancer treatment approach; prostate cancer treatment intensification; prostate cancer biomarkers; radiomics and artificial intelligence (AI)
Special Issue Information
Dear Colleagues,
For several decades, prostate cancer has remained a significant health concern, impacting men in the later stages of their lives. In contemporary times, extensive research in all phases of this affliction has permitted us to better understand the mechanisms of disease progression and bring us closer to a cure. Our improved discernment of all facets of prostate cancer has provided opportunities to improve outcomes and toxicities by exploiting modern technologies, developing intensified treatment algorithms, and discovering altogether new and innovative therapeutic approaches.
In the last few years, several new trends in prostate cancer have arisen, and others are currently being explored. We invite researchers to discuss these new trends in prostate cancer in this Special Issue of Current Oncology.
Dr. Tamim Niazi
Guest Editor
Dr. Steven Tisseverasinghe
Co-Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate SBRT
- recurrent prostate cancer
- treatment intensification with ARPIs
- PARP inhibitors
- lutetium-177
- immunotherapy
- oligometastases
